Summary
This prediction ended on 21.01.19 with a price of €3.12. With a performance of -2.35%, the BUY prediction for 4 SC AG by melinda closed slightly in the red. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| 4 SC AG | - | - | - | - |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by melinda for this prediction
In the thread 4 SC AG diskutieren
SecteurRecherche biotechnologique et médicale Agenda 25/10 Publication de résultats
4SC AG engages in the development of small molecule drugs that targets cancer through epigenetic mechanisms.
It also involves in the preclinical and clinical development of its products.
Its assets are resminostat, 4SC-202, and 4SC-208.
The company was founded by Ulrich Dauer, Daniel Vitt, Stefan Busemann, and Klaus-Peter Gulden in 1997 and is headquartered in Planegg-Martinsried, Germany.
Nombre d'employés : 48 personnes.